Global Cerebral Palsy Treatment Market

Cerebral Palsy Treatment Comprehensive Study by Type (Medications (Musel or Nerve Injections and Oral Muscle Relaxants), Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy), Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers), Others), Application (Hospitals, Clinics, Others), Diagnosis (Brain Scans (MRI and Cranial Ultrasound), Electroencephalogram (EEG), Laboratory Tests (Blood), Disorder Type (Spastic Cerebral Palsy, Dyskinetic Cerebral Palsy, Hypotonic Cerebral Palsy, Ataxic Cerebral Palsy, Mixed Cerebral Palsy) Players and Region - Global Market Outlook to 2026

Cerebral Palsy Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cerebral Palsy Treatment Market?

Cerebral palsy affects over 500,000 people in the United States and one in approximately 345 kids has cerebral palsy. Cerebral palsy is a neuromuscular disorder that affects movement and muscle tone or posture. It is a neurological condition caused by brain damage. It is the most common motor and movement disability in children. It is more common in boys than in girls. Currently, there is no cure for this disorder. The treatment options available helps to improve the child's daily life, health and well-being. There are various treatment options available for this disease involving medications, therapies, surgical procedures and alternative medicines. It depends on type of disorder as well as the severity of the disorder.

The market study is being classified by Type (Medications (Musel or Nerve Injections and Oral Muscle Relaxants), Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy), Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers) and Others), by Application (Hospitals, Clinics and Others) and major geographies with country level break-up.

Allergan Plc (United States), Cellular Biomedicine Group (United States), Merck & Co., Inc. (United States), Pfizer, Inc. (United States), GlaxoSmithKline Plc (United Kingdom), Abbott Laboratories (United States), Acorda Therapeutics, Inc. (United States), Medtronic plc (Ireland), Meridigen Biotech Co., Ltd. (China), GW Pharmaceuticals Plc (United Kingdom) and Cell Cure Neurosciences Ltd. (Israel) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cerebral Palsy Treatment market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Cerebral Palsy Treatment market by Type, Application and Region.

On the basis of geography, the market of Cerebral Palsy Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increased Prevalence of Cerebral Palsy in Children
  • High Demand for Complete Cure Treatment for Cerebral Palsy
  • Development of New Diagnostic Centre and Hospitals

Market Trend
  • Rise in the Research and Development Activities

Restraints
  • Side Effects of the Medicines of Disorder

Opportunities
  • Huge Investments by the Major Players
  • Increase in Healthcare Expenditure
  • Growth In Healthcare Industry Worldwide

Challenges
  • Less Awareness about Cerebral Palsy among People





Key Target Audience
Cerebral Palsy Treatment Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

Report Objectives / Segmentation Covered

By Type
  • Medications (Musel or Nerve Injections and Oral Muscle Relaxants)
  • Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy)
  • Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers)
  • Others
By Application
  • Hospitals
  • Clinics
  • Others
By Diagnosis
  • Brain Scans (MRI and Cranial Ultrasound)
  • Electroencephalogram (EEG)
  • Laboratory Tests (Blood

By Disorder Type
  • Spastic Cerebral Palsy
  • Dyskinetic Cerebral Palsy
  • Hypotonic Cerebral Palsy
  • Ataxic Cerebral Palsy
  • Mixed Cerebral Palsy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cerebral Palsy in Children
      • 3.2.2. High Demand for Complete Cure Treatment for Cerebral Palsy
      • 3.2.3. Development of New Diagnostic Centre and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness about Cerebral Palsy among People
    • 3.4. Market Trends
      • 3.4.1. Rise in the Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cerebral Palsy Treatment, by Type, Application, Diagnosis, Disorder Type and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cerebral Palsy Treatment (Value)
      • 5.2.1. Global Cerebral Palsy Treatment by: Type (Value)
        • 5.2.1.1. Medications (Musel or Nerve Injections and Oral Muscle Relaxants)
        • 5.2.1.2. Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy)
        • 5.2.1.3. Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers)
        • 5.2.1.4. Others
      • 5.2.2. Global Cerebral Palsy Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global Cerebral Palsy Treatment by: Diagnosis (Value)
        • 5.2.3.1. Brain Scans (MRI and Cranial Ultrasound)
        • 5.2.3.2. Electroencephalogram (EEG)
        • 5.2.3.3. Laboratory Tests (Blood
      • 5.2.4. Global Cerebral Palsy Treatment by: Disorder Type (Value)
        • 5.2.4.1. Spastic Cerebral Palsy
        • 5.2.4.2. Dyskinetic Cerebral Palsy
        • 5.2.4.3. Hypotonic Cerebral Palsy
        • 5.2.4.4. Ataxic Cerebral Palsy
        • 5.2.4.5. Mixed Cerebral Palsy
      • 5.2.5. Global Cerebral Palsy Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cerebral Palsy Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan Plc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Cellular Biomedicine Group (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck & Co., Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline Plc (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Acorda Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Medtronic plc (Ireland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Meridigen Biotech Co., Ltd. (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. GW Pharmaceuticals Plc (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Cell Cure Neurosciences Ltd. (Israel)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Cerebral Palsy Treatment Sale, by Type, Application, Diagnosis, Disorder Type and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cerebral Palsy Treatment (Value)
      • 7.2.1. Global Cerebral Palsy Treatment by: Type (Value)
        • 7.2.1.1. Medications (Musel or Nerve Injections and Oral Muscle Relaxants)
        • 7.2.1.2. Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy)
        • 7.2.1.3. Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers)
        • 7.2.1.4. Others
      • 7.2.2. Global Cerebral Palsy Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global Cerebral Palsy Treatment by: Diagnosis (Value)
        • 7.2.3.1. Brain Scans (MRI and Cranial Ultrasound)
        • 7.2.3.2. Electroencephalogram (EEG)
        • 7.2.3.3. Laboratory Tests (Blood
      • 7.2.4. Global Cerebral Palsy Treatment by: Disorder Type (Value)
        • 7.2.4.1. Spastic Cerebral Palsy
        • 7.2.4.2. Dyskinetic Cerebral Palsy
        • 7.2.4.3. Hypotonic Cerebral Palsy
        • 7.2.4.4. Ataxic Cerebral Palsy
        • 7.2.4.5. Mixed Cerebral Palsy
      • 7.2.5. Global Cerebral Palsy Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cerebral Palsy Treatment: by Type(USD Million)
  • Table 2. Cerebral Palsy Treatment Medications (Musel or Nerve Injections and Oral Muscle Relaxants) , by Region USD Million (2015-2020)
  • Table 3. Cerebral Palsy Treatment Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy) , by Region USD Million (2015-2020)
  • Table 4. Cerebral Palsy Treatment Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers) , by Region USD Million (2015-2020)
  • Table 5. Cerebral Palsy Treatment Others , by Region USD Million (2015-2020)
  • Table 6. Cerebral Palsy Treatment: by Application(USD Million)
  • Table 7. Cerebral Palsy Treatment Hospitals , by Region USD Million (2015-2020)
  • Table 8. Cerebral Palsy Treatment Clinics , by Region USD Million (2015-2020)
  • Table 9. Cerebral Palsy Treatment Others , by Region USD Million (2015-2020)
  • Table 10. Cerebral Palsy Treatment: by Diagnosis(USD Million)
  • Table 11. Cerebral Palsy Treatment Brain Scans (MRI and Cranial Ultrasound) , by Region USD Million (2015-2020)
  • Table 12. Cerebral Palsy Treatment Electroencephalogram (EEG) , by Region USD Million (2015-2020)
  • Table 13. Cerebral Palsy Treatment Laboratory Tests (Blood , by Region USD Million (2015-2020)
  • Table 14. Cerebral Palsy Treatment: by Disorder Type(USD Million)
  • Table 15. Cerebral Palsy Treatment Spastic Cerebral Palsy , by Region USD Million (2015-2020)
  • Table 16. Cerebral Palsy Treatment Dyskinetic Cerebral Palsy , by Region USD Million (2015-2020)
  • Table 17. Cerebral Palsy Treatment Hypotonic Cerebral Palsy , by Region USD Million (2015-2020)
  • Table 18. Cerebral Palsy Treatment Ataxic Cerebral Palsy , by Region USD Million (2015-2020)
  • Table 19. Cerebral Palsy Treatment Mixed Cerebral Palsy , by Region USD Million (2015-2020)
  • Table 20. South America Cerebral Palsy Treatment, by Country USD Million (2015-2020)
  • Table 21. South America Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 22. South America Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 23. South America Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 24. South America Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 25. Brazil Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 26. Brazil Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 27. Brazil Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 28. Brazil Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 29. Argentina Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 30. Argentina Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 31. Argentina Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 32. Argentina Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 33. Rest of South America Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 36. Rest of South America Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 37. Asia Pacific Cerebral Palsy Treatment, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 41. Asia Pacific Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 42. China Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 43. China Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 44. China Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 45. China Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 46. Japan Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 47. Japan Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 48. Japan Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 49. Japan Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 50. India Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 51. India Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 52. India Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 53. India Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 54. South Korea Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 55. South Korea Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 56. South Korea Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 57. South Korea Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 58. Taiwan Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 59. Taiwan Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 60. Taiwan Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 61. Taiwan Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 62. Australia Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 63. Australia Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 64. Australia Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 65. Australia Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 70. Europe Cerebral Palsy Treatment, by Country USD Million (2015-2020)
  • Table 71. Europe Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 72. Europe Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 73. Europe Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 74. Europe Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 75. Germany Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 76. Germany Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 77. Germany Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 78. Germany Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 79. France Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 80. France Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 81. France Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 82. France Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 83. Italy Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 84. Italy Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 85. Italy Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 86. Italy Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 87. United Kingdom Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 90. United Kingdom Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 91. Netherlands Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 92. Netherlands Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 93. Netherlands Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 94. Netherlands Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 95. Rest of Europe Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 98. Rest of Europe Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 99. MEA Cerebral Palsy Treatment, by Country USD Million (2015-2020)
  • Table 100. MEA Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 101. MEA Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 102. MEA Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 103. MEA Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 104. Middle East Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 105. Middle East Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 106. Middle East Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 107. Middle East Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 108. Africa Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 109. Africa Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 110. Africa Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 111. Africa Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 112. North America Cerebral Palsy Treatment, by Country USD Million (2015-2020)
  • Table 113. North America Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 114. North America Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 115. North America Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 116. North America Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 117. United States Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 118. United States Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 119. United States Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 120. United States Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 121. Canada Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 122. Canada Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 123. Canada Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 124. Canada Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 125. Mexico Cerebral Palsy Treatment, by Type USD Million (2015-2020)
  • Table 126. Mexico Cerebral Palsy Treatment, by Application USD Million (2015-2020)
  • Table 127. Mexico Cerebral Palsy Treatment, by Diagnosis USD Million (2015-2020)
  • Table 128. Mexico Cerebral Palsy Treatment, by Disorder Type USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Cerebral Palsy Treatment: by Type(USD Million)
  • Table 141. Cerebral Palsy Treatment Medications (Musel or Nerve Injections and Oral Muscle Relaxants) , by Region USD Million (2021-2026)
  • Table 142. Cerebral Palsy Treatment Therapies (Physical Therapy, Occupational Therapy, Speech and Language Therapy and Recreational Therapy) , by Region USD Million (2021-2026)
  • Table 143. Cerebral Palsy Treatment Surgical Procedures (Orthopedic Surgery and Cutting Nerve Fibers) , by Region USD Million (2021-2026)
  • Table 144. Cerebral Palsy Treatment Others , by Region USD Million (2021-2026)
  • Table 145. Cerebral Palsy Treatment: by Application(USD Million)
  • Table 146. Cerebral Palsy Treatment Hospitals , by Region USD Million (2021-2026)
  • Table 147. Cerebral Palsy Treatment Clinics , by Region USD Million (2021-2026)
  • Table 148. Cerebral Palsy Treatment Others , by Region USD Million (2021-2026)
  • Table 149. Cerebral Palsy Treatment: by Diagnosis(USD Million)
  • Table 150. Cerebral Palsy Treatment Brain Scans (MRI and Cranial Ultrasound) , by Region USD Million (2021-2026)
  • Table 151. Cerebral Palsy Treatment Electroencephalogram (EEG) , by Region USD Million (2021-2026)
  • Table 152. Cerebral Palsy Treatment Laboratory Tests (Blood , by Region USD Million (2021-2026)
  • Table 153. Cerebral Palsy Treatment: by Disorder Type(USD Million)
  • Table 154. Cerebral Palsy Treatment Spastic Cerebral Palsy , by Region USD Million (2021-2026)
  • Table 155. Cerebral Palsy Treatment Dyskinetic Cerebral Palsy , by Region USD Million (2021-2026)
  • Table 156. Cerebral Palsy Treatment Hypotonic Cerebral Palsy , by Region USD Million (2021-2026)
  • Table 157. Cerebral Palsy Treatment Ataxic Cerebral Palsy , by Region USD Million (2021-2026)
  • Table 158. Cerebral Palsy Treatment Mixed Cerebral Palsy , by Region USD Million (2021-2026)
  • Table 159. South America Cerebral Palsy Treatment, by Country USD Million (2021-2026)
  • Table 160. South America Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 161. South America Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 162. South America Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 163. South America Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 164. Brazil Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 165. Brazil Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 166. Brazil Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 167. Brazil Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 168. Argentina Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 169. Argentina Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 170. Argentina Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 171. Argentina Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 172. Rest of South America Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 173. Rest of South America Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 174. Rest of South America Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 175. Rest of South America Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 176. Asia Pacific Cerebral Palsy Treatment, by Country USD Million (2021-2026)
  • Table 177. Asia Pacific Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 178. Asia Pacific Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 179. Asia Pacific Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 180. Asia Pacific Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 181. China Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 182. China Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 183. China Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 184. China Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 185. Japan Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 186. Japan Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 187. Japan Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 188. Japan Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 189. India Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 190. India Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 191. India Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 192. India Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 193. South Korea Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 194. South Korea Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 195. South Korea Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 196. South Korea Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 197. Taiwan Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 198. Taiwan Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 199. Taiwan Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 200. Taiwan Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 201. Australia Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 202. Australia Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 203. Australia Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 204. Australia Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 207. Rest of Asia-Pacific Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 209. Europe Cerebral Palsy Treatment, by Country USD Million (2021-2026)
  • Table 210. Europe Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 211. Europe Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 212. Europe Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 213. Europe Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 214. Germany Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 215. Germany Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 216. Germany Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 217. Germany Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 218. France Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 219. France Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 220. France Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 221. France Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 222. Italy Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 223. Italy Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 224. Italy Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 225. Italy Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 226. United Kingdom Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 227. United Kingdom Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 228. United Kingdom Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 229. United Kingdom Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 230. Netherlands Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 231. Netherlands Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 232. Netherlands Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 233. Netherlands Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 234. Rest of Europe Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 235. Rest of Europe Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 236. Rest of Europe Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 237. Rest of Europe Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 238. MEA Cerebral Palsy Treatment, by Country USD Million (2021-2026)
  • Table 239. MEA Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 240. MEA Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 241. MEA Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 242. MEA Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 243. Middle East Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 244. Middle East Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 245. Middle East Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 246. Middle East Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 247. Africa Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 248. Africa Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 249. Africa Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 250. Africa Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 251. North America Cerebral Palsy Treatment, by Country USD Million (2021-2026)
  • Table 252. North America Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 253. North America Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 254. North America Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 255. North America Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 256. United States Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 257. United States Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 258. United States Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 259. United States Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 260. Canada Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 261. Canada Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 262. Canada Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 263. Canada Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 264. Mexico Cerebral Palsy Treatment, by Type USD Million (2021-2026)
  • Table 265. Mexico Cerebral Palsy Treatment, by Application USD Million (2021-2026)
  • Table 266. Mexico Cerebral Palsy Treatment, by Diagnosis USD Million (2021-2026)
  • Table 267. Mexico Cerebral Palsy Treatment, by Disorder Type USD Million (2021-2026)
  • Table 268. Research Programs/Design for This Report
  • Table 269. Key Data Information from Secondary Sources
  • Table 270. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cerebral Palsy Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Cerebral Palsy Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Cerebral Palsy Treatment: by Diagnosis USD Million (2015-2020)
  • Figure 7. Global Cerebral Palsy Treatment: by Disorder Type USD Million (2015-2020)
  • Figure 8. South America Cerebral Palsy Treatment Share (%), by Country
  • Figure 9. Asia Pacific Cerebral Palsy Treatment Share (%), by Country
  • Figure 10. Europe Cerebral Palsy Treatment Share (%), by Country
  • Figure 11. MEA Cerebral Palsy Treatment Share (%), by Country
  • Figure 12. North America Cerebral Palsy Treatment Share (%), by Country
  • Figure 13. Global Cerebral Palsy Treatment share by Players 2020 (%)
  • Figure 14. Global Cerebral Palsy Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Cerebral Palsy Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Allergan Plc (United States) Revenue, Net Income and Gross profit
  • Figure 18. Allergan Plc (United States) Revenue: by Geography 2020
  • Figure 19. Cellular Biomedicine Group (United States) Revenue, Net Income and Gross profit
  • Figure 20. Cellular Biomedicine Group (United States) Revenue: by Geography 2020
  • Figure 21. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 25. GlaxoSmithKline Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 29. Acorda Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Acorda Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 32. Medtronic plc (Ireland) Revenue: by Geography 2020
  • Figure 33. Meridigen Biotech Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 34. Meridigen Biotech Co., Ltd. (China) Revenue: by Geography 2020
  • Figure 35. GW Pharmaceuticals Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. GW Pharmaceuticals Plc (United Kingdom) Revenue: by Geography 2020
  • Figure 37. Cell Cure Neurosciences Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 38. Cell Cure Neurosciences Ltd. (Israel) Revenue: by Geography 2020
  • Figure 39. Global Cerebral Palsy Treatment: by Type USD Million (2021-2026)
  • Figure 40. Global Cerebral Palsy Treatment: by Application USD Million (2021-2026)
  • Figure 41. Global Cerebral Palsy Treatment: by Diagnosis USD Million (2021-2026)
  • Figure 42. Global Cerebral Palsy Treatment: by Disorder Type USD Million (2021-2026)
  • Figure 43. South America Cerebral Palsy Treatment Share (%), by Country
  • Figure 44. Asia Pacific Cerebral Palsy Treatment Share (%), by Country
  • Figure 45. Europe Cerebral Palsy Treatment Share (%), by Country
  • Figure 46. MEA Cerebral Palsy Treatment Share (%), by Country
  • Figure 47. North America Cerebral Palsy Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan Plc (United States)
  • Cellular Biomedicine Group (United States)
  • Merck & Co., Inc. (United States)
  • Pfizer, Inc. (United States)
  • GlaxoSmithKline Plc (United Kingdom)
  • Abbott Laboratories (United States)
  • Acorda Therapeutics, Inc. (United States)
  • Medtronic plc (Ireland)
  • Meridigen Biotech Co., Ltd. (China)
  • GW Pharmaceuticals Plc (United Kingdom)
  • Cell Cure Neurosciences Ltd. (Israel)
Select User Access Type

Key Highlights of Report


Jan 2022 243 Pages 95 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cerebral Palsy Treatment Market Quantitative research analysis
Global Cerebral Palsy Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Cerebral Palsy in Children " is seen as one of major growth factors of Cerebral Palsy Treatment Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
United States will lead Cerebral Palsy Treatment Market in coming years.

Know More About Global Cerebral Palsy Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Premature Ejaculation Comprehensive Study by Type (Lifelong (Primary), Acquired (Secondary)), Application (Hospitals, Clinics), Treatment (Medical Therapy, Non-Medical Therapy) Players and Region - G...
$ 3500
Lyme Disease Diagnostics Comprehensive Study by Diagnostic Technology (Serological Test (ELISA, Western Blot), Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nuclei...
$ 3450
Psoriatic Arthritis Treatment Comprehensive Study by Treatment (Medications (NSAIDs, Disease-modifying antirheumatic drugs (DMARDs), Immunosuppressants, Biologic Agents and Others), Surgical Procedur...
$ 3750
Gene expression analysis Comprehensive Study by Type (Consumables (Reagents, DNA Chips), Instruments (PCR, NGS, Microarray)), Application (Diagnostics, Pharmacogenomics, Toxicology, Compare Expressio...
$ 3750
Edible Vaccines Comprehensive Study by Type (Inactivated Vaccines, Others), Application (Medical Care, Livestock, Others) Players and Region - Global Market Outlook to 2030
$ 3500
Valley Fever Treatment Comprehensive Study by Application (People, Cattle, Sheep and Goats, Camel, Others), Treatment for Pets (Fluconazole (Diflucan), Itraconazole (Sporanox), Ketoconazole (Nizoral)...
$ 3450